Pancholy Maitri, Storey Philip P, Wood Edward H, Chaudhary Varun, Obeid Anthony, Marlow Elizabeth, Farley Nathan D, Wolfe Jeremy D, Garg Sunir J
Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, PA, USA.
Department of Ophthalmology, Emory University, Atlanta, GA, USA.
J Vitreoretin Dis. 2022 Aug 25;6(5):358-366. doi: 10.1177/24741264221109376. eCollection 2022 Sep-Oct.
To compare the incidence and visual outcomes of endophthalmitis after injection of an intravitreal dexamethasone implant and injection of intravitreal ranibizumab.
This retrospective cohort study assessed endophthalmitis in eyes receiving an intravitreal injection of a 0.7 mg dexamethasone implant (DEX group), 0.5 mg ranibizumab (R5 group), or 0.3 mg ranibizumab (R3 group) between January 1, 2016, and May 31, 2018, at 2 large retina practices in the United States.
Suspected endophthalmitis occurred in 5 eyes after 4973 DEX injections, 43 eyes after 163 974 R5 injections, and 6 eyes after 18 954 R3 injections. Suspected endophthalmitis was significantly more common in the DEX group (1/995) than in the R5 group (1/3813) ( = .008) but not than in the R3 group (1/3159) ( = .10). Visual acuity outcomes were similar in the 3 groups.
Suspected endophthalmitis might be more common after 0.7 mg dexamethasone injections than after 0.5 mg ranibizumab injections. Culture-positive endophthalmitis rates were similar across all 3 medications.
比较玻璃体内注射地塞米松植入剂和玻璃体内注射雷珠单抗后眼内炎的发生率和视力预后。
这项回顾性队列研究评估了2016年1月1日至2018年5月31日期间在美国两家大型视网膜诊所接受玻璃体内注射0.7毫克地塞米松植入剂（DEX组）、0.5毫克雷珠单抗（R5组）或0.3毫克雷珠单抗（R3组）的眼睛的眼内炎情况。
在4973次DEX注射后有5只眼发生疑似眼内炎，在163974次R5注射后有43只眼发生疑似眼内炎，在18954次R3注射后有6只眼发生疑似眼内炎。DEX组（1/995）疑似眼内炎的发生率显著高于R5组（1/3813）（P = 0.008），但与R3组（1/3159）相比无显著差异（P = 0.10）。三组的视力预后相似。
0.7毫克地塞米松注射后疑似眼内炎可能比0.5毫克雷珠单抗注射后更常见。所有三种药物的培养阳性眼内炎发生率相似。
